ADJSYN

Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses

Coordinatore	GlaxoSmithKline Biologicals    more  Organization address address: Rue de l'Institut 89 city: Rixensart postcode: 1330 contact info Titolo: Dr. Nome: Philippe Cognome: Denoel Email: send email Telefono: 3226564032
Nazionalità Coordinatore	Belgium [BE]
Totale costo	169˙800 €
EC contributo	169˙800 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-07-01   -   2015-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	GlaxoSmithKline Biologicals  Organization address address: Rue de l'Institut 89 city: Rixensart postcode: 1330 contact info Titolo: Dr. Nome: Philippe Cognome: Denoel Email: send email Telefono: 3226564032	BE (Rixensart)	coordinator	169˙800.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

The need to develop vaccines against challenging diseases such as malaria or tuberculosis requires effective adjuvants to improve the immune responses against purified antigens, as these antigens often lack intrinsic immunogenicity. Most adjuvants act on innate immunity leading to the activation of antigen presenting cells and induction of memory T cell and antibody responses to the vaccine. Including more than one immunostimulant within an adjuvant has the capacity to improve the quality of the immune response to a vaccine. In this respect, combinatorial adjuvants may emulate aspects of the natural immune response to a pathogen, which involves multiple innate pathways typically triggered by stimuli from pathogen-derived molecules. GSK Vaccines has pioneered the use of immunostimulants in adjuvant formulations for human vaccines. One of its propriety Adjuvant Systems, AS01, is a liposome-based and contains the immunostimulants MPL and QS-21. In pre-clinical models, antigen-specific cellular immune responses are synergistically enhanced with the combination of MPL and QS-21. Hence the overall scientific objective of the ADJSYN project is to understand the basis of the MPL and QS-21 synergy by focussing on key molecular and cellular mediators of the synergistic response, and on how these mediators interact. This project will use a multidisciplinary approach, involving bioinformatics, immunology, imaging and molecular biology, and will be conducted through several collaborations within Europe. Therefore ADJSYN should deliver mechanistic insights on how to engage innate immune pathways to promote effective adaptive immune responses; and the methodology should be transferable for the analysis of adjuvants formulated with other immunostimulants. Moreover, because AS01 is being evaluated in an increasing number of vaccines, the insights from this project could have direct relevance for translational research and the rationale design of new human vaccines.